Evotec stock narrows Q3 EBITDA loss as 2026 outlook holds

Evotec reported third-quarter and nine-month 2026 results on Thursday, November 5, adding detail to the preliminary figures released ahead of the full report. The PR Newswire release published by Yahoo Finance showed a sharp improvement in quarterly adjusted EBITDA, but a weaker nine-month revenue trend.

Quarterly profitability improves

Group revenue reached 164.9 million euros in the third quarter, broadly matching the prior-year quarter. Adjusted Group EBITDA improved to a loss of 1.6 million euros from a loss of 15.0 million euros, with Evotec attributing the change mainly to lower cost of revenue.

For the first nine months, revenue fell 13.1% year on year to 465.0 million euros. Adjusted Group EBITDA declined to a loss of 44.3 million euros from a loss of 16.9 million euros in the prior-year period, as the revenue decline outweighed savings in the cost base. Liquidity stood at 400.9 million euros at the end of September.

Guidance and strategy remain in focus

Evotec reaffirmed its 2026 outlook for group revenue of 570 million to 610 million euros and adjusted EBITDA of minus 105 million to minus 70 million euros. The company also presented a 2030 framework targeting around 1 billion euros in group revenue, an adjusted EBITDA margin of 20% by the end of 2028 and more than 20% by the end of 2030.

Execution indicators were mixed but included several positive developments. Net sales in the Discovery and Preclinical Development base business rose 24% in the first nine months, while more than 20% of the 75 million euro annual run-rate savings target had been delivered by the end of September. Evotec also confirmed that Just - Evotec Biologics was selected by Vertex Pharmaceuticals for commercial manufacturing of povetacicept.

Evotec stock after the results

Evotec stock traded at 3.08 euros on Lang & Schwarz at 17:43 CET on Thursday, November 5, 2026, 0.32% below the Xetra close of Thursday, November 5. Investors now face the task of weighing stronger quarterly execution and cost savings against the nine-month revenue decline and the continuing cash and profitability pressure. The real-time quote of Evotec stock provides the latest trading reference.

German equities remain the broader backdrop for Evotec, with the DAX providing the main market reference.

More news and analyses on Evotec stock